Franklin Resources Inc. Purchases Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Franklin Resources Inc. acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 520,301 shares of the company’s stock, valued at approximately $7,435,000. Franklin Resources Inc. owned 2.14% of Artiva Biotherapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in Artiva Biotherapeutics during the third quarter valued at about $42,000. MetLife Investment Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $135,000. Barclays PLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $304,000. Charles Schwab Investment Management Inc. purchased a new position in Artiva Biotherapeutics in the third quarter valued at approximately $623,000. Finally, Acuta Capital Partners LLC acquired a new position in Artiva Biotherapeutics during the third quarter valued at approximately $680,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ARTV. Wedbush restated an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, August 30th. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $21.25.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $11.11 on Monday. Artiva Biotherapeutics, Inc. has a 1 year low of $9.68 and a 1 year high of $17.31. The stock’s 50-day simple moving average is $11.64.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). Equities research analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current year.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.